![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/DRREDDY.png)
Share the post "DRREDDYS LABORATORIES ‘s Q3 2024-25 Latest News: Revenue Up by 15.81% Year-on-Year"
Highlights
🔹 The presented financial data is Consolidated to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 15.81 % in the past year, substantial increase in net sales/revenue by 4.27 %. 🔹 Income over the Year and quarter: There has been decline in other income over the past year which is -30.53 %, Marginal decrease of -51.15% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for DR.REDDYS LABORATORIES LTD.. Notable increase of 1.69 % in net profit Year to Year, DR.REDDYS LABORATORIES LTD.’s profitability increased by 4.64 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 2.29 % Year to Year. EPS increased by 12.53 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 7236.8 Cr | Rs. 8038.2 Cr | Rs. 8381.2 Cr | + 4.27 % | + 15.81 % |
| Expenses | Rs. 5213.7 Cr | Rs. 5961.7 Cr | Rs. 6108.2 Cr | + 2.46 % | + 17.16 % |
| Operating Profit | Rs. 2023.1 Cr | Rs. 2076.5 Cr | Rs. 2273 Cr | + 9.46 % | + 12.35 % |
| OPM % | 27.96 % | 25.83 % | 27.12 % | + 1.29 % | -0.84 % |
| Other Income | Rs. 216.2 Cr | Rs. 307.5 Cr | Rs. 150.2 Cr | -51.15 % | -30.53 % |
| Interest | Rs. 39.4 Cr | Rs. 75.7 Cr | Rs. 81.7 Cr | + 7.93 % | + 107.36 % |
| Depreciation | Rs. 373.5 Cr | Rs. 397 Cr | Rs. 471.4 Cr | + 18.74 % | + 26.21 % |
| Profit before tax | Rs. 1826.4 Cr | Rs. 1911.3 Cr | Rs. 1870.1 Cr | -2.16 % | + 2.39 % |
| Tax % | 24.54 % | 30.11 % | 25.14 % | -4.97 % | + 0.6 % |
| Net Profit | Rs. 1380.9 Cr | Rs. 1341.9 Cr | Rs. 1404.2 Cr | + 4.64 % | + 1.69 % |
| EPS in Rs | Rs. 16.56 | Rs. 15.05 | Rs. 16.94 | + 12.56 % | + 2.29 % |
Today, we’re looking at DR.REDDYS LABORATORIES LTD.’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 15.81 %. However, it did see a marginal increase of 4.27 % from the previous quarter. Expenses ticked up slightly by 2.46 % quarter-on-quarter, aligning with the annual rise of 17.16 %. Operating profit, while up 12.35 % compared to last year, faced a quarter-on-quarter increase of 9.46 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % contradicts this narrative, showing weakness on an annual basis with a decrease of -0.84 %, but an expansion of 1.29 % sequentially. Other income fell by -51.15 % compared to the last quarter, despite an annual decline of -30.53 %. Interest expenses surged remarkably by 7.93 % from the previous quarter, yet the year-over-year increase remains at a moderate 107.36 %. Depreciation costs climbed by 18.74 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 26.21 %. Profit before tax grew annually by 2.39 % but saw a reduction from the preceding quarter by -2.16 %.
Tax expenses as a percentage of profits increased slightly by 0.6 % compared to last year, with a more notable quarter-on-quarter decrease of -4.97 %. Net profit rose by 1.69 % year-on-year but experienced a 4.64 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 2.29 % but a quarterly rise of 12.56 %. In summary, DR.REDDYS LABORATORIES LTD.’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 7236.8 Cr | Rs. 8038.2 Cr | Rs. 8381.2 Cr | + 4.27 % | + 15.81 % |
| Expenses | Rs. 5213.7 Cr | Rs. 5961.7 Cr | Rs. 6108.2 Cr | + 2.46 % | + 17.16 % |
| Operating Profit | Rs. 2023.1 Cr | Rs. 2076.5 Cr | Rs. 2273 Cr | + 9.46 % | + 12.35 % |
| Net Profit | Rs. 1380.9 Cr | Rs. 1341.9 Cr | Rs. 1404.2 Cr | + 4.64 % | + 1.69 % |
| EPS in Rs | Rs. 16.56 | Rs. 15.05 | Rs. 16.94 | + 12.56 % | + 2.29 % |
In reviewing DR.REDDYS LABORATORIES LTD.’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 15.81 % year-on-year growth, however, there was a minor increase of 4.27 % from the previous quarter. Expenses rose by 17.16 % compared to the previous year, with a 2.46 % increase quarter-on-quarter. Operating Profit surged by 12.35 % annually, and saw a 9.46 % increase from the last quarter.
Net Profit showed yearly increase of 1.69 %, and experienced a 4.64 % increase from the previous quarter. Earnings Per Share (EPS) rose by 2.29 % annually, however rose by 12.56 % compared to the last quarter. In essence, while DR.REDDYS LABORATORIES LTD. exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
